Aclaris Therapeutics to Attend Upcoming Investor Conferences

MALVERN, Pa., Nov. 03, 2017 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a dermatologist-led biopharmaceutical company focused on identifying, developing and commercializing innovative and differentiated therapies to address significant unmet needs in medical and aesthetic dermatology, today announced that members of its management team will present and host investor meetings at the following upcoming investor events:

• Dr. Neal Walker, President and Chief Executive Officer, will present at the Jefferies 2017 London Healthcare Conference in London, UK on Thursday, November 16, 2017 at 10:40 AM GMT. Management will also host investor meetings on both Wednesday, November 15, 2017 and Thursday, November 16, 2017.    
• Dr. Neal Walker, President and Chief Executive Officer, will present at the Leerink Annual POLARxPress Conference in New York, NY on Tuesday, November 28, 2017 at 10:45 AM EST.
• Dr. Neal Walker, President and Chief Executive Officer, will present at the 29th Annual Piper Jaffray Healthcare Conference in New York, NY on Wednesday, November 29, 2017 at 12:30 PM EST. Management will also host investor meetings on Wednesday, November 29, 2017.
• Management will host investor meetings during Citi’s 2017 Global Healthcare Conference in New York, NY on Thursday, December 7, 2017.
• Management will host investor meetings during Guggenheim’s 5th Annual Boston Healthcare Conference in Boston, MA on Wednesday, December 13, 2017.

A live webcast of the Jefferies 2017 London Healthcare Conference presentation and the 29th Annual Piper Jaffray Healthcare Conference presentation may be accessed through the Company's web site, www.aclaristx.com, on the 'Events and Presentations' section. An archived version of the presentation will be available for 30 days.

About Aclaris Therapeutics, Inc.Aclaris Therapeutics, Inc. is a dermatologist-led biopharmaceutical company focused on identifying, developing and commercializing innovative and differentiated therapies to address significant unmet needs in medical and aesthetic dermatology.  Aclaris is focused on large, underserved market segments with no FDA-approved medications or where treatment gaps exist.  Aclaris is based in Malvern, Pennsylvania and more information can be found by visiting the Aclaris website at www.aclaristx.com.

Contact:

Aclaris ContactMichael Tung, M.D. Vice President / Investor Relations484-329-2140[email protected]

Media ContactMariann CaprinoTogoRun917-242-1087[email protected]

You May Also Be Interested In

• Amylyx Pharmaceuticals inc. (AMLX) PT Raised to $55 at Guggenheim
• The Crypto Bull Run Is Back and the Wallets Getting In Early Are Already Inside Pepeto
• Citi upgrades O-I Glass to Buy with $9 price target, opens 90-Day upside catalyst watch